BioGaia AB Class B BIOG B
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 101.16M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 33.15
- Price/Sales
- 7.30
- Dividend Yield (Trailing)
- 1.44%
- Dividend Yield (Forward)
- 1.44%
- Dividend Payment Schedule
- May
- Total Yield
- 1.44%
Company Profile
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 251
- Website
- https://www.biogaiagroup.com
Valuation
|
Metric
|
BIOG B
|
|---|---|
Price/Earnings (Normalized) | 33.15 |
Price/Book Value | 10.47 |
Price/Sales | 7.30 |
Price/Cash Flow | 33.70 |
Price/Earnings
BIOG B
Financial Strength
|
Metric
|
BIOG B
|
|---|---|
Quick Ratio | 2.11 |
Current Ratio | 4.44 |
Interest Coverage | 74.96 |
Quick Ratio
BIOG B
Profitability
|
Metric
|
BIOG B
|
|---|---|
Return on Assets (Normalized) | 23.00% |
Return on Equity (Normalized) | 28.04% |
Return on Invested Capital (Normalized) | 27.78% |
Return on Assets
BIOG B
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|!VL#%D? | LOCK|%>LW | $67B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|?<#wfqRq | LOCK|Tbn> | $46B | |||
| Haleon PLC ADR
HLN
| LOCK|p>m%%kQ | LOCK|&Sm | $38B | |||
| Zoetis Inc Class A
ZTS
| LOCK|&h#bQ>#K | LOCK|x&g | $29B | |||
| Viatris Inc
VTRS
| LOCK|k?^?X^V | LOCK|&d | $20B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|bC# | LOCK|dw | $11B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|G#XVMz | LOCK|%J | $10B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|nr#St# | LOCK|z> | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|tKQ#dtv | LOCK|BmNb | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|C$MC@> | LOCK|^D< | $2B |
United States